EUVIMEDEUVIMED entdecken
Crossref

Cytotoxic CD39 + tumor-associated NK cells respond to NKG2A blockade in lung cancer

Clara Serger iD, Lucas Rebuffet iD, Michael T Sandholzer iD, Wiebke Rackwitz iD, Irene Fusi iD, Petra Herzig iD, Annalea Brüggemann, Carina A Pawlow, Evgeny Chichelnitskiy iD, Daniel Hajnal iD, Nicole Oelgarth iD, Sarp Uzun iD und 19 weitere

Science Immunology · 05.06.2026 · 11 (120)

DOI: 10.1126/sciimmunol.aeb6645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 05.06.2026. Verfasst von Clara Serger und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: Killer Cells, Natural, Lung Neoplasms, NK Cell Lectin-Like Receptor Subfamily C, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: Roche, Swiss Cancer League.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cell–targeting immunotherapies are emerging, yet the differentiation and functional states of tumor-infiltrating NK cells remain poorly understood. Using matched single-nucleus RNA and ATAC sequencing of samples from patients with non–small cell lung cancer (NSCLC), we resolved the transcriptional and epigenetic landscape of intratumoral NK cells. We identified two tumor-associated NK (taNK) cell subsets marked by expression of ITGAE (CD103) and ITGA1 (CD49a) that display features of tissue residency and dysfunction while preserving cytotoxic function. Trajectory and regulon analyses revealed an inflammation-driven transition from early granzyme K ( GZMK ) + NK cells toward an ENTPD1 + (CD39 + ) effector state characterized by interferon-stimulated gene (ISG) programs. Functional profiling established CD39 + taNK cells as the dominant cytotoxic NK cell population with superior killing capacity that was further potentiated by NKG2A blockade. This study offers mechanistic insights into NK cell differentiation in NSCLC and establishes CD39 + taNK cells as a targetable effector population for immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Killer Cells, NaturalLung NeoplasmsNK Cell Lectin-Like Receptor Subfamily CCarcinoma, Non-Small-Cell LungApyraseHumansAntigens, CDCytotoxicity, ImmunologicIntegrin alpha Chains

Substanzen

NK Cell Lectin-Like Receptor Subfamily CApyraseAntigens, CDKLRC1 protein, humanENTPD1 protein, humanIntegrin alpha Chains

Autor:innen und Institutionen

  • Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland.
  • Aix Marseille Université, CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy, Marseille, France.
  • Institute of Transplant Immunology, Hannover Medical School, Hannover, Germany.
  • Institute of Pathology, University Hospital and University of Basel, Basel, Switzerland.
  • Roche Pharma Research and Early Development pRED, Roche Innovation Center, Basel, Switzerland.
  • Department of Thoracic Surgery, University Hospital Basel, Basel, Switzerland.

ORCID-Profile: Clara Serger, Lucas Rebuffet, Michael T Sandholzer, Wiebke Rackwitz, Irene Fusi, Petra Herzig, Evgeny Chichelnitskiy, Daniel Hajnal, Nicole Oelgarth, Sarp Uzun, Christoph Schultheiß, Andreas Zingg, Sofia Tundo, Aljaz Hojski, Mascha Binder, Kirsten Mertz, Marcel P Trefny, Nicole Kirchhammer, Marina Natoli, Matthias S Matter, Heinz Läubli, Christine Falk, Karin Schaeuble, Eric Vivier, Alfred Zippelius

Förderung

  • Roche
  • Swiss Cancer League

Zitieren

APA

Serger, C., Rebuffet, L., Sandholzer, M. T., Rackwitz, W., Fusi, I., Herzig, P., Brüggemann, A., Pawlow, C. A., Chichelnitskiy, E., Hajnal, D., Oelgarth, N., Uzun, S., Schultheiß, C., Zingg, A., Tundo, S., Luu, T. T., Hojski, A., Lardinois, D., Neubert, L., …, & Zippelius, A. (2026). Cytotoxic CD39 + tumor-associated NK cells respond to NKG2A blockade in lung cancer. Science Immunology, 11(120). https://doi.org/10.1126/sciimmunol.aeb6645

Vancouver

Serger C, Rebuffet L, Sandholzer MT, Rackwitz W, Fusi I, Herzig P, et al. Cytotoxic CD39 + tumor-associated NK cells respond to NKG2A blockade in lung cancer. Science Immunology. 2026;11(120). doi:10.1126/sciimmunol.aeb6645

BibTeX
@article{Serger2026,
  author = {Serger, Clara and Rebuffet, Lucas and Sandholzer, Michael T and Rackwitz, Wiebke and Fusi, Irene and Herzig, Petra and Brüggemann, Annalea and Pawlow, Carina A and Chichelnitskiy, Evgeny and Hajnal, Daniel and Oelgarth, Nicole and Uzun, Sarp and Schultheiß, Christoph and Zingg, Andreas and Tundo, Sofia and Luu, Thuy T and Hojski, Aljaz and Lardinois, Didier and Neubert, Lavinia and Binder, Mascha and Mertz, Kirsten and Trefny, Marcel P and Kirchhammer, Nicole and Natoli, Marina and Matter, Matthias S and Läubli, Heinz and Falk, Christine and Schaeuble, Karin and Vivier, Eric and Romagnani, Andrea and Zippelius, Alfred},
  title = {Cytotoxic CD39 + tumor-associated NK cells respond to NKG2A blockade in lung cancer},
  journal = {Science Immunology},
  year = {2026},
  volume = {11},
  number = {120},
  doi = {10.1126/sciimmunol.aeb6645}
}
Kostenlos starten →